Side effects of electrochemotherapy in cats with squamous cell carcinoma: a retrospective study

Ana Rita Zeferino^{1,2}, Joaquim Henriques¹, Ana Faustino-Rocha^{2,3}, Ana Rita Serras²

¹Hospital Veterinário de Berna, Onevet group, Lisbon, Portugal. ²Faculdade de Medicina Veterinária da Universidade Lusófona de Humanidades e Tecnologias, Lisbon, Portugal. ³Department of Zootechnics, School of Sciences and Technology, University of Évora, Évora, Portugal

Electrochemotherapy (EQT) is an emerging therapeutic modality in Veterinary Oncology that combines the intravenous (IV) or intratumoral (IT) administration of chemotherapeutic agents with the application of electrical pulses⁽¹⁾. This therapy has been described to induce significant cancer remission in cutaneous squamous cell carcinoma (SCC) and a reduction of chemotherapeutic dosages, maximizing intracellular concentration of these drugs as well as reducing its systemic side effects^(2,3).

Objectives

The aim of this study was to describe the side effects observed in cats with a cytological or histopathological diagnosis of oral or cutaneous squamous cell carcinoma (SCC) of the head submitted to EQT as a primary treatment.

Methods

The medical records of cats treated with EQT for SCC at the “Onevet Group - Hospital Veterinário de Berna” between December 2015 and February 2018 were reviewed. Cats with a cytologic and/or histopathologic diagnosis of head SCC (cutaneous and oral) that received at least one session of EQT were eligible for inclusion. Cats with incomplete clinical record or without a cyto/histopathological report were excluded. Side effects data were retrospectively classified using the Common Terminology Criteria for Adverse Events Following Chemotherapy or Biological Antineoplastic Therapy in Dogs and Cats v1.1 (VCOG-CTCAE)⁽⁴⁾.

Results

- Seventeen cats were treated for a total of 28 EQT sessions; The number of treatments per cat were: 1 session (52.9%); 2 (35.3%); 3 (5.9%) and 4 sessions (5.9%).**
- SCC lesions treated were localized on the nasal planum (70.6%), eyelid (11.8%), oral (5.9%), both on the pinna and eyelid (5.9%) and on the pinna and face (5.9%).**
- EQT treatments were performed using bleomycin in all cases (94% IV and 6% IT).**
- Adverse events reported *per cat* and *per total* of treatments, are described in Figure 1 (top and bottom, respectively).
- All cats had a reported adverse event at least once;**
- Pain and soft tissue necrosis were present in all cats.**
- The percentage of severity of adverse events are described in Figure 2. **Ninety six percent of adverse events reported were grade I to III.**

Adverse Events reported per cat

Adverse Events reported per total of EQT treatments

Figure 1 – Absolute count and percentage of adverse events reported described according to VCOG-CTCAE⁴.

Severity of Adverse Events

Figure 2 – Percentage of Severity of Adverse Events according to VCOG-CTCAE⁴.

Figure 3 – Pictures showing the clinical evolution of one of the cats treated with EQT for palpebral cutaneous SCC (courtesy of referring veterinary surgeon Dr. AR Serras);

Discussion/Conclusion

Pain, soft tissue necrosis and constitutional side effects were the most frequent adverse events, reported in more than 70% of cats included in this study. Most side effects were grade I to III according to VCOG-CTCAE and tolerable. This is comparable with previous studies of EQT in cats^(1,5,6).

Limitations of this study include its retrospective nature, small number of cases and inclusion of different locations of SCC within the head.

Further larger prospective studies accessing clinical response and side effects are warranted to promote a more conscious application of EQT. It would also be interesting to include in those future studies scales to measure the impact of EQT in cats Quality of life.

(1) Spugnini, E.P., Fanciulli, M., Citro, G., Baldi, A. (2012). Preclinical models in electrochemo-therapy: the role of veterinary patients. *Future Oncol* 8, 829–837.
(2) Ciriál, H. C., Lopez, D. S. (2001). La electroquimioterapia: una nueva alternativa terapéutica en la oncología. *Rev Cubana Oncol*, 17, 188–194.
(3) Mir, L.M., Glass, L.F., Sersa, G., Teissie, J., Domenge, C., Mikiavici, D., et al. (1988). Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. *Br J Cancer* 77, 2336–2342.
(4) VCOG-CTCAE (2011). Veterinary terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. *Vet Comp Oncol* 14: 417–446.
(5) Spugnini, E.P., Vincenzi, B., Citro, G., Tonini, G., Dotsinsky, I., Mudrov, N. et al. (2009). Electrochemotherapy for the treatment of squamous cell carcinoma in cats: a preliminary report. *Vet J* 179, 117–120.
(6) Spugnini, E.P., Azzarito, T., Fais, S., Fanciulli, M., Baldi, A. (2016). Electrochemotherapy as first line cancer treatment: experiences from veterinary medicine in developing novel protocols. *Curr Cancer Drug Targets* 16, 43–52.